Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial Noureddin et al. Published: October 5, 2023

https://www.thelancet.com/journals/langas/home